Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
CD19/BCMA-targeted CAR-T lentiviral vector drug(Shenzhen Genocury Biotech) in Sjogren's Syndrome: NCT07490951 Clinical Landscape Report 2026
18 September 2026
NCT07490951 clinical landscape for Sjogren's Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SHR-3836 in Multiple Myeloma: NCT07490613 Clinical Landscape Report 2026
18 September 2026
NCT07490613 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT07490288 Clinical Landscape Report 2026
18 September 2026
NCT07490288 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Myositis: NCT07490275 Clinical Landscape Report 2026
18 September 2026
NCT07490275 clinical landscape for Myositis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IMV-102 in Relapse multiple myeloma: NCT07493135 Clinical Landscape Report 2026
18 September 2026
NCT07493135 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Renal Pelvis and Ureter Urothelial Carcinoma: NCT07492628 Clinical Landscape Report 2026
18 September 2026
NCT07492628 clinical landscape for Renal Pelvis and Ureter Urothelial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
CD19/CD20/FCGR trispecific antibody(Hinge Bio) in Lupus Nephritis: NCT07491900 Clinical Landscape Report 2026
18 September 2026
NCT07491900 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-CD19/BCMA CAR-NK Cells(The Children's Hospital of Zhejiang University School of Medicine) in Sjogren's Syndrome: NCT07490041 Clinical Landscape Report 2026
18 September 2026
NCT07490041 clinical landscape for Sjogren's Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Chondroitin Sulfate Sodium in Cystitis: NCT07495072 Clinical Landscape Report 2026
18 September 2026
NCT07495072 clinical landscape for Cystitis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Revumenib in Acute Myeloid Leukemia: NCT07498465 Clinical Landscape Report 2026
18 September 2026
NCT07498465 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Methotrexate Sodium in Psoriasis vulgaris: CTRI/2026/03/107054 Clinical Landscape Report 2026
18 September 2026
CTRI/2026/03/107054 clinical landscape for Psoriasis vulgaris: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Xeligekimab in Pustulosis of Palms and Soles: NCT07503652 Clinical Landscape Report 2026
18 September 2026
NCT07503652 clinical landscape for Pustulosis of Palms and Soles: endpoints, sponsor, phase, geography, readouts, asset context and development white space.